Genetic Technologies Ltd (GENE) - Rasio cepet

Genetic Technologies (GENE) specializes in high-tech diagnostics. Intellectual property protection and strict government licenses create significant barriers to entry for new players, and the current indicator stands at 0.79. This price chart helps assess the asset's dynamics. The business is implementing AI systems and robotics to automate the analysis of oncology risks. The sector is considered a defensive asset, as the demand for medical research remains independent of global economic fluctuations.

For Genetic Technologies (GENE), this indicator assesses the company's ability within the genetic diagnostics sector to settle short-term debts without liquidating inventory. The metric compares the most liquid assets—cash and accounts receivable—against current liabilities. Analyzing the acid-test ratio allows for tracking the impact of currency fluctuations on the issuer's solvency. Optimizing expenditures on reagents and plastics under the ESG strategy indirectly supports the business's financial stability.